Welcome to Merz Therapeutics North America

At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life.

Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is headquartered in Frankfurt, Germany and is represented in more than 90 countries. Our Merz Therapeutics North America business is composed of affiliates in the U.S. and Canada and has regional headquarters in Raleigh, N.C. To visit the Merz Canada website and for more information on our Canada business, please click here.

Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.

News

MERZ THERAPEUTICS TO PRESENT KEY DATA ON XEOMIN® (incobotulinumtoxinA) AT TOXINS 2021 VIRTUAL CONFERENCE

RALEIGH, N.C., January 15, 2021

Merz Therapeutics announced today the presentation of data from 18 accepted abstracts on XEOMIN® (incobotulinumtoxinA) at TOXINS 2021: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins, taking place virtually January 16 and 17.

INFOGRAPHIC: XEOMIN® (incobotulinumtoxinA) PEDIATRIC CHRONIC SIALORRHEA

RALEIGH, N.C., December 21, 2020

XEOMIN® (incobotulinumtoxinA) is now approved by the FDA for the treatment of patients aged 2 years and older with chronic sialorrhea, or drooling. XEOMIN is the first and only FDA-approved neuromodulator with this indication. Download our infographic detailing our latest approval.

FDA APPROVES PEDIATRIC INDICATION FOR XEOMIN® (incobotulinumtoxinA) FOR THE TREATMENT OF CHRONIC SIALORRHEA

RALEIGH, N.C., December 21, 2020

Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for XEOMIN® (incobotulinumtoxinA) for the treatment of patients aged 2 years and older with chronic sialorrhea, or drooling. XEOMIN is the first and only FDA-approved neuromodulator with this indication and was granted a priority review designation upon acceptance by the FDA.

Contact Us

Title*
Name*
Phone*
Email*
City*
State*
Message*
If you would like to report a possible side effect or complaint for a therapeutic product in the United States, please contact 844-469-6379 (844-4MY-MERZ). For reports regarding therapeutic products in Canada, please click here.
CAPTCHA
Comments
This field is for validation purposes and should be left unchanged.

* mandatory fields

Please note that if you submit information to Merz all materials submitted by electronic or physical communication will be deemed non-confidential. Do not submit any information or other materials that you consider to be confidential or proprietary. While we have no intention to publicly disclose any details of your proposal, we may refer to select experts within or outside the Merz network for evaluation.